TrueLab TrueLab Care
Evidence reviews · DOI-cited sources · research use only
Guide 17 Nov 2026 · 3 min read · 3 sources

What “research grade” means for an incretin peptide, and what it does not

A vial labelled retatrutide from a research supplier and a pen labelled retatrutide from a pharmaceutical company may contain the same sequence. They are not the same product, and the difference has nothing to do with purity percentages. It is about what has been proven, by whom, and under what obligation.

TL

TrueLab Research Team

Reviewed 17 Nov 2026 · Summarises peer-reviewed literature · Not medical advice

Key takeaways

  • A pharmaceutical-grade product is manufactured under Good Manufacturing Practice, with every batch released against a validated specification and a regulator able to inspect the site.
  • A research-grade reagent is characterised, not released: a certificate of analysis reports what was measured on that lot, and that is the whole of the guarantee.
  • Sterility, endotoxin, and the identity of every impurity are routinely not tested on a research reagent, because the reagent is not intended to enter a body.
  • The trial literature describes the pharmaceutical product. It transfers to a research reagent only to the extent the reagent has been shown to be the same molecule.
  • The practical question is never “is it pure?” but “what does the certificate actually say was measured, and by which method?”

The phrase "research grade" is used as if it were a quality tier, somewhere below pharmaceutical and above industrial. It is not a tier. It is a statement about intended use, and everything that follows from it is about what was and was not checked.

Pharmaceutical grade is a system, not a number

A licensed medicine is made under Good Manufacturing Practice. That phrase covers a great deal: a validated process that produces the same material every time, a specification that every batch must meet before release, a qualified person who signs that it does, a stability programme that proves the shelf life, and a regulator who can walk into the factory unannounced.

The specification for a therapeutic peptide, following the ICH Q6B framework, typically covers identity by at least two methods, purity, each individual impurity above a threshold, total content, water, residual solvents, counter-ion, appearance, sterility, bacterial endotoxin and more1. A batch that fails any one of them is not released.

Crucially, the clinical trials were run on material that met that specification. When the literature says retatrutide produced a given result, it means retatrutide manufactured to that standard did.

Research grade is a characterisation

A research reagent is sold for use in a laboratory, in an assay, in a cell culture, in an animal model. It is not intended to enter a human body, and so the tests that exist to make injection safe are not run.

What a research supplier provides instead is a certificate of analysis for the lot: typically identity by mass spectrometry and purity by HPLC, sometimes net peptide content, sometimes water. The certificate reports what was measured. It does not promise that anything not listed is acceptable, because nothing not listed was checked.

What a release specification covers vs what a typical research CoA covers

Number of parameter categories, illustrative

Research CoA: identity + purity 2 categories Pharma release: identity, purity, impurities, content, sterility, endotoxin, water, counter-ion, appearance 9+ categories

Based on ICH Q6B specification categories and typical peptide CoA content. Chart by TrueLab Care.

Sterility is the clearest case. A pharmaceutical injectable is tested to confirm the absence of viable microorganisms and of endotoxin, the bacterial cell-wall fragments that cause fever. A research reagent is not, because in a cell-culture assay or a receptor-binding experiment those parameters either do not matter or are controlled downstream. The reagent is not less pure; it is simply not characterised for a purpose it was not sold for.

Why this matters more for incretin peptides than for most

Three features of the GLP-1 class make the distinction sharper than usual.

They are large, modified peptides with a fatty-acid chain, and the synthesis is difficult. The space of possible impurities, truncated sequences, incompletely acylated species, oxidised residues, is wider than for a short unmodified peptide.

They are dosed weekly with a half-life of days, so any impurity that is present persists.

And they have unusually high commercial demand, which is the condition under which analytical studies have found online products with content far from label. A 2024 study that test-purchased semaglutide from online sellers found that the active content exceeded the label by 29 to 39 per cent while measured purity was between 7.7 and 14.4 per cent, against advertised figures near 9923. Those were products sold for human use without a prescription, not research reagents, but the analytical finding is the point: a label is a claim until a chromatogram supports it.

Reading a certificate correctly

The useful questions are not "what is the purity?" but these:

Was identity confirmed by mass spectrometry, and does the observed mass match the theoretical mass for the full modified peptide including the fatty-acid chain? A mass match for the bare sequence without the chain is a different molecule.

Is the HPLC chromatogram shown, or only a number? A number without a trace cannot be checked.

Is the net peptide content stated separately from purity? Purity is the fraction of the peptide-related material that is the right peptide; content is how much of the vial's mass is peptide at all. A vial of 99 per cent pure peptide at 70 per cent content contains 30 per cent water and counter-ion.

What is not on the certificate? Sterility and endotoxin almost never are. That absence is normal for a reagent and is the reason a reagent is not a medicine.

The honest summary

The trial literature for retatrutide, tirzepatide and the rest describes molecules made to a pharmaceutical specification, tested on every batch, and administered under protocol. A research reagent bearing the same name is characterised to a narrower standard for a different purpose. The sequence may be identical. The evidence that it is identical rests entirely on the certificate, and the certificate only ever says what was measured.

References

  1. 1. International Council for Harmonisation ICH Q6B: Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products. ICH 1999 database.ich.org ↩
  2. 2. Ashraf AR, Mackey TK, Schmidt J, et al. Safety and Risk Assessment of No-Prescription Online Semaglutide Purchases. JAMA Network Open 2024 ; 7(8):e2428280 doi:10.1001/jamanetworkopen.2024.28280 ↩
  3. 3. Ashraf AR, Mackey TK, Schmidt J, et al. Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription. Journal of Medical Internet Research 2024 ; 26:e65440 doi:10.2196/65440 ↩

This article summarises published research for educational purposes. It is not medical advice and does not describe permitted uses of any product. Compounds discussed are supplied strictly for in-vitro laboratory research and are not for human or animal consumption.

Continue reading

All The Lab →